Jun 20, 2022 - 16 min
With up to 90% efficacy, it's also cheaper and easier to store than other candidates. The Phase III results of Oxford-AstraZeneca's vaccine were announced this Monday, to much anticipation after Pfizer & BioNTech and Moderna announced theirs last week. While slightly less effective than the other two, the Oxford-AstraZeneca vaccine — which works based on a harmless adenovirus from a chimpanzee — has a few advantages over them, such as ease of distribution and being priced at cost, at least during the pandemic. Clive Cookson and Donato Paolo Mancini explain in the Financial Times all we need to know about it.